- Charles River Laboratories has launched the Charles River Incubator Program (CIP) to support early-stage biotechnology companies in developing advanced therapies.
- The CIP builds on the success of the company’s CGT Accelerator Program, offering expertise, training, and access to facilities.
Charles River Laboratories has announced the launch of its Charles River Incubator Program (CIP), aimed at helping early-stage biotechnology companies navigate the discovery, development, and manufacturing of advanced therapies. The program, part of the company’s Global Innovation Center of Excellence, focuses on providing knowledge, regulatory guidance, and access to facilities for startups over 24 months from IND or CTA submission.
This initiative expands on the company’s existing Cell and Gene Therapy Accelerator Program (CAP), which supports developers 18–24 months from IND or CTA submission. Both programs leverage Charles River’s “concept to cure” capabilities, integrating drug discovery, safety assessment, and clinical to commercial contract development and manufacturing expertise.
Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River, highlighted the company’s commitment, saying, “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offering knowledge, connectivity, and priority access to the Charles River portfolio.”
The CIP is anchored at the company’s CDMO Center of Excellence in Alderley Park, the UK’s largest life science ecosystem. The facility integrates a cross-functional team of scientific and regulatory experts, providing essential support for incubator participants.
The first CIP cohort will be selected by March 2025, coinciding with the upcoming Cell and Gene Therapy Summit in San Francisco.
Stay ahead of trends and best practices
